TW200524846A - Novel compounds - Google Patents
Novel compounds Download PDFInfo
- Publication number
- TW200524846A TW200524846A TW093138533A TW93138533A TW200524846A TW 200524846 A TW200524846 A TW 200524846A TW 093138533 A TW093138533 A TW 093138533A TW 93138533 A TW93138533 A TW 93138533A TW 200524846 A TW200524846 A TW 200524846A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- formula
- group
- acid
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 131
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 36
- -1 2-Bromo-5-fluorenylphenyl Chemical group 0.000 claims description 63
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 35
- 125000003277 amino group Chemical group 0.000 claims description 26
- 239000002253 acid Substances 0.000 claims description 21
- 235000019260 propionic acid Nutrition 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 17
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 13
- 108010044426 integrins Proteins 0.000 claims description 11
- 102000006495 integrins Human genes 0.000 claims description 10
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 210000000265 leukocyte Anatomy 0.000 claims description 9
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 230000021164 cell adhesion Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 230000000172 allergic effect Effects 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- UIMPAOAAAYDUKQ-UHFFFAOYSA-N 1-methoxy-4-(4-methoxyphenyl)benzene Chemical group C1=CC(OC)=CC=C1C1=CC=C(OC)C=C1 UIMPAOAAAYDUKQ-UHFFFAOYSA-N 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- 230000008595 infiltration Effects 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 239000001294 propane Substances 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010056979 Colitis microscopic Diseases 0.000 claims description 2
- 208000027932 Collagen disease Diseases 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 208000027530 Meniere disease Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010038563 Reocclusion Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 206010038848 Retinal detachment Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000029076 Synovial disease Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 230000003872 anastomosis Effects 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000004982 autoimmune uveitis Diseases 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 208000008609 collagenous colitis Diseases 0.000 claims description 2
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000003903 intestinal lesions Effects 0.000 claims description 2
- 208000004341 lymphocytic colitis Diseases 0.000 claims description 2
- 230000000527 lymphocytic effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 208000004396 mastitis Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 230000004264 retinal detachment Effects 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000005747 tumor angiogenesis Effects 0.000 claims description 2
- 210000001635 urinary tract Anatomy 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- NLWCWEGVNJVLAX-UHFFFAOYSA-N 1-methoxy-2-phenylbenzene Chemical group COC1=CC=CC=C1C1=CC=CC=C1 NLWCWEGVNJVLAX-UHFFFAOYSA-N 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 206010006811 Bursitis Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000001738 Nervous System Trauma Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040968 SLE arthritis Diseases 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000010339 dilation Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000035922 thirst Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 33
- 238000011282 treatment Methods 0.000 abstract description 12
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 150000002993 phenylalanine derivatives Chemical class 0.000 abstract description 2
- 230000023578 negative regulation of cell adhesion Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 47
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 239000007787 solid Substances 0.000 description 26
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 22
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 125000004494 ethyl ester group Chemical group 0.000 description 11
- 125000006239 protecting group Chemical group 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 235000019341 magnesium sulphate Nutrition 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000004575 stone Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- XBUYOTVVBBQADZ-UHFFFAOYSA-N 2-bromo-5-ethoxybenzoic acid Chemical compound CCOC1=CC=C(Br)C(C(O)=O)=C1 XBUYOTVVBBQADZ-UHFFFAOYSA-N 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 108010041012 Integrin alpha4 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 4
- 101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 4
- 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- OJVSEHLMRCLAFY-UHFFFAOYSA-N methyl propanoate;hydrochloride Chemical compound Cl.CCC(=O)OC OJVSEHLMRCLAFY-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000003254 radicals Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000002821 scintillation proximity assay Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- JJWFIVDAMOFNPS-QRPNPIFTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JJWFIVDAMOFNPS-QRPNPIFTSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ODHJOROUCITYNF-UHFFFAOYSA-N 2-bromo-5-methoxybenzoic acid Chemical compound COC1=CC=C(Br)C(C(O)=O)=C1 ODHJOROUCITYNF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- GPSDUZXPYCFOSQ-UHFFFAOYSA-N m-toluenecarboxylic acid Natural products CC1=CC=CC(C(O)=O)=C1 GPSDUZXPYCFOSQ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- PIZJKAUDQZSKPQ-UHFFFAOYSA-N methyl 2-bromo-5-sulfanylbenzoate Chemical compound COC(=O)c1cc(S)ccc1Br PIZJKAUDQZSKPQ-UHFFFAOYSA-N 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- ZPIZAFSIMHXFRS-UHFFFAOYSA-N oxolane propanoic acid Chemical compound O1CCCC1.C(CC)(=O)O ZPIZAFSIMHXFRS-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- IFXORIIYQORRMJ-UHFFFAOYSA-N tribenzylphosphane Chemical compound C=1C=CC=CC=1CP(CC=1C=CC=CC=1)CC1=CC=CC=C1 IFXORIIYQORRMJ-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 238000009834 vaporization Methods 0.000 description 2
- 230000008016 vaporization Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 238000001238 wet grinding Methods 0.000 description 2
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- LZBLCOBTBFHEJX-UHFFFAOYSA-N (4-cyano-2,6-dimethoxyphenyl)boronic acid Chemical compound COC1=CC(C#N)=CC(OC)=C1B(O)O LZBLCOBTBFHEJX-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- WVUYYXUATWMVIT-UHFFFAOYSA-N 1-bromo-4-ethoxybenzene Chemical compound CCOC1=CC=C(Br)C=C1 WVUYYXUATWMVIT-UHFFFAOYSA-N 0.000 description 1
- JUQPJJFSZJPLPK-UHFFFAOYSA-N 1-butoxy-9h-fluorene Chemical compound C1C2=CC=CC=C2C2=C1C(OCCCC)=CC=C2 JUQPJJFSZJPLPK-UHFFFAOYSA-N 0.000 description 1
- WNYHOOQHJMHHQW-UHFFFAOYSA-N 1-chloropyrene Chemical compound C1=C2C(Cl)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 WNYHOOQHJMHHQW-UHFFFAOYSA-N 0.000 description 1
- SQQKOTVDGCJJKI-UHFFFAOYSA-N 2,5-dibromobenzoic acid Chemical compound OC(=O)C1=CC(Br)=CC=C1Br SQQKOTVDGCJJKI-UHFFFAOYSA-N 0.000 description 1
- PYAXBACITOQDMT-UHFFFAOYSA-N 2-(2-bromoethoxy)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1OCCBr PYAXBACITOQDMT-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- IQRUSQUYPCHEKN-UHFFFAOYSA-N 2-iodobutane Chemical compound CCC(C)I IQRUSQUYPCHEKN-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 1
- KQKQQRHOZQCRPZ-UHFFFAOYSA-N 4-bromo-3,5-dimethoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC(OC)=C1Br KQKQQRHOZQCRPZ-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- RQVGGXSXVWLCBB-UHFFFAOYSA-N BrC1=C(C=C(C=C1)F)C1=CC=CC=2C3=CC=CC=C3CC12 Chemical compound BrC1=C(C=C(C=C1)F)C1=CC=CC=2C3=CC=CC=C3CC12 RQVGGXSXVWLCBB-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- DXZYNGBGSTXBQE-UHFFFAOYSA-N C(C)(C)[Mo] Chemical compound C(C)(C)[Mo] DXZYNGBGSTXBQE-UHFFFAOYSA-N 0.000 description 1
- UENWPZVMJUKMPF-UHFFFAOYSA-N C1CCCC=2OC3=CC=CC=C3C(C1=2)O Chemical compound C1CCCC=2OC3=CC=CC=C3C(C1=2)O UENWPZVMJUKMPF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282988 Capreolus Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- MUXOBHXGJLMRAB-UHFFFAOYSA-N Dimethyl succinate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 108010041014 Integrin alpha5 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 206010027234 Meningitis eosinophilic Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100027069 Odontogenic ameloblast-associated protein Human genes 0.000 description 1
- 101710091533 Odontogenic ameloblast-associated protein Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 208000002389 Pouchitis Diseases 0.000 description 1
- 101100247669 Quaranfil virus (isolate QrfV/Tick/Afghanistan/EG_T_377/1968) PB1 gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 101150025928 Segment-1 gene Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- 101100242902 Thogoto virus (isolate SiAr 126) Segment 1 gene Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- UXRDAJMOOGEIAQ-CKOZHMEPSA-N [(8r,9s,10r,13s,14s,17r)-17-acetyl-10,13-dimethyl-16-methylidene-3-oxo-1,2,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UXRDAJMOOGEIAQ-CKOZHMEPSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000005215 alkyl ethers Chemical group 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- WEHASWIUGWHFHD-UHFFFAOYSA-N argon;thionyl dichloride Chemical compound [Ar].ClS(Cl)=O WEHASWIUGWHFHD-UHFFFAOYSA-N 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- VJWWIRSVNSXUAC-UHFFFAOYSA-N arsinic acid Chemical compound O[AsH2]=O VJWWIRSVNSXUAC-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- TXKMVPPZCYKFAC-UHFFFAOYSA-N disulfur monoxide Chemical compound O=S=S TXKMVPPZCYKFAC-UHFFFAOYSA-N 0.000 description 1
- BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 201000009449 eosinophilic meningitis Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 description 1
- MHMQGJBUQUDINX-UHFFFAOYSA-N ethoxybenzene Chemical compound [CH2]COC1=CC=CC=C1 MHMQGJBUQUDINX-UHFFFAOYSA-N 0.000 description 1
- DZWPQVIPTOYHLR-NTISSMGPSA-N ethyl (2s)-2-amino-3-[4-(4-cyano-2,6-dimethoxyphenyl)phenyl]propanoate;hydrochloride Chemical compound Cl.C1=CC(C[C@H](N)C(=O)OCC)=CC=C1C1=C(OC)C=C(C#N)C=C1OC DZWPQVIPTOYHLR-NTISSMGPSA-N 0.000 description 1
- OUZCDRGUTZLAGO-UHFFFAOYSA-N ethyl 2-ethoxybenzoate Chemical compound CCOC(=O)C1=CC=CC=C1OCC OUZCDRGUTZLAGO-UHFFFAOYSA-N 0.000 description 1
- YJJCBPAEWVURMJ-UHFFFAOYSA-N ethyl propanoate;hydrochloride Chemical compound Cl.CCOC(=O)CC YJJCBPAEWVURMJ-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000005206 intestinal lamina propria Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- AIWIFVOBRBJANE-UHFFFAOYSA-N methyl 2-bromo-5-hydroxybenzoate Chemical compound COC(=O)C1=CC(O)=CC=C1Br AIWIFVOBRBJANE-UHFFFAOYSA-N 0.000 description 1
- YKUCHDXIBAQWSF-UHFFFAOYSA-N methyl 3-hydroxybenzoate Chemical compound COC(=O)C1=CC=CC(O)=C1 YKUCHDXIBAQWSF-UHFFFAOYSA-N 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluenecarboxylic acid Natural products CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N ortho-methoxybenzoic acid Natural products COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- BWILYWWHXDGKQA-UHFFFAOYSA-M potassium propanoate Chemical compound [K+].CCC([O-])=O BWILYWWHXDGKQA-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
Description
200524846 九、發明說明: 【發明所屬之技術領域】 本發明係有關新穎化合物、其製備方法、包括其之組 成物以及其於治療或預防疾病上之利用,該疾病或不適係 可經由抑制細胞黏著而控制。更特定言之,本發明係有關 新穎苯丙胺酸衍生物,其會抑制α4整合素(integrin)所媒 介之細胞黏著,故認為可用於治療或預防炎症疾病。 【先前技術】 白血球與内皮細胞或細胞外間質蛋白之間的多重黏 _ 著交互作用為免疫及發炎調節作用之關鍵因子。白血球自 發炎處之血管移動離開的最早事件包括:白血球滾動,隨 後整合素活動性改變,此導致隨後穩固之附著(參照 Butcher, Cell 67:1033-1036 (1991); Harlan, Blood 3:513-525 (1985); Hemler, Annu. Rev. Immunol. 8:365-400 (1990); Osborn, Cell 62:3-6 (1990); Shimizu et al.?
Immunol. Rev. 114:109-143 (1990); Springer, Nature 346:425-434 (1990))。回應趨化因子,白血球會移動穿過 兩鄰近内皮細胞並進入部分由細胞外間質蛋白纖維結合素 (fibronectin, FN) ($- ^ Wayner et al.? J. Cell Biol. 105:1873-1884 (1987))及膠原蛋白(CN)(參見 Bornstein et al·,Ann· Rev. Biochem. 49:957-1003 (1980);以及 Miller, Chemistry of the collagens and their distribution,於 “Extracellular Matrix Biochemistry” 5 K.A. Piez and A. H. Reddi,editors,Elsevier,Amsterdam,41-78 (1983))戶斤組成 5 316565 200524846 之組織。麥與此等黏著反應之重要辨識分子係屬於整合素 基因超級家族的成員(參見hv· /則浙?0/· 8:365-400 (1990); Hynes, Ce// 48:549-554 (1987); Shimizu et al·,/m則⑽/· hv· 114:1〇9_143 (199〇);以及 Sprmger, 346:425-434 (1990)) ° 整合素為由非共價結合之次單元所組成的雜二聚體 (heterodimer),該次單元係指α與占次單元。迄今,已鑑 定出8種整合素/5次單元,其可與16種不同α次單元結合 以形成至少23種不同整合素。 α 4 /5 !整合素,亦被稱為VLA-4 (極遲抗原-4),係構 成性地表現於白血球(包括淋巴球、單核球、嗜酸性白血球 及嗜鹼性白血球)表面(參見Hemler et al·,CTzem. 262:11478-11485 (1987); W&B〇Chneretal.,J.£Xp.U· 173:1553-15 56 (1991))。經報告指出VLA-4係存在於敗血 症病患之嗜中性白血球上(參見Ibbotson et al.,Nature Med 7:465-470 (2001))。VLA-4會結合至已活化内皮細胞上之 血管細胞黏者分子-1 (VCAM -1)’致使白血球外渗(elices et al·,Ce// 60:577-5 84 (1990))。一旦當該細胞到達血管外 之空間時’則VLA-4可結合至連結片段-1 (connecting segment-1,CS-1),該連接片段-1為fn A鏈之可變剪接區 (alternatively spliced region)(Wayne et al.? J. Cell Biol. 109:1321-1330 (1989))。此外,已知VLA-4會結合至造骨 蛋白,該造骨蛋白為動脈硬化斑塊中經上調(upregulated) 之蛋白(參見 Bayless et al·,J. ☆// Sczhce 111:1165-1174 6 316565 200524846 (1998))。 α 4冷7整合素,亦知為LPAM-1 (淋巴球-集合淋巴結 (Peyer、patch )黏著分子-1),會與三種已知配位子 (VCAM-1、CS-1、MAdCAM-Ι)相互作用。黏膜位址素細胞 黏著分子(Mucosal Addressin Cell Adhesion Molecule -1, MAdCAM-1)為對a 4 /3 7顯現獨特專一性之一種配位子(參 ^ Andrew et al.? J. Immunol. 153:3847-3861 (1994);
Briskin et al.,TVWt/re 363:461-464 (1993);以及 Shyjan et al·, J· /mmw^zo/· 156:2851-2857 (1996))。MAdCAM-1 高度表現 於集合淋巴結高内皮小靜脈上、腸系膜淋巴結内、以及腸 黏膜固有層與乳腺小靜脈上(Berg et al·,/mm關〇/·及ev· 105:5-18 (1989))。顯示整合素 α 4/5 7 與 MAdCAM-1 於調節 淋巴球歸巢遷移(trafficking)至正常腸部係相當重要 (Holzmann et al·,Ce// 56:37-46 (1989)) 〇 此外,已有文獻述及整合素《4冷1及石7之口服 生物可利用之非胜肽小分子拮抗劑可用於治療或預防如氣 喘、發炎性腸道疾病、類風濕性關節炎、多發性硬化症及 其他疾病之症狀(參見專利說明書WO 99/363 93及W〇 02/18320,其說明書之内容以參考文獻方式納入本文)。 目前所發現之新種類化合物係落於專利說明書WO 99/36393之一般範圍内,但並未明確揭露於其中。 【發明内容】 於第一實施態樣中,本發明係提供式(I)化合物或其醫 藥上可接受之衍生物: 316565 200524846
式中 R1為〉臭;以及 R2為鹵素、Ci_6垸基或c“院氧基。 較佳者,^為_素或c]_6烧氧基。 更佳者,R2為氟、甲氧基或乙氧基。 、於其他實施態樣中,本發明係提供E1至E7 (如下述) 或其醫藥上可接受之衍生物,亦即 (S)-2-{[l-(2-濞_5·乙氧基苯基)甲醯基]胺基卜3-(4,-氰 基2,6 -一甲氧基聯笨_4_基)丙酸; (S)-2-{[l-(2-溴-5-氟笨基)甲醯基]胺基卜3-(4,_氰基 2,6 -二曱氧基聯笨_4_基)丙酸; (S)-2-{[l-(2-溴-5-曱氧基苯基)曱醯基]胺基卜3_(4,_氰 基-2,6’-二曱氧基聯苯基)丙酸; (8)-2-{[1-(2-溴-5-曱基苯基)曱醯基]胺基卜3-(4,-氰基 -2,6、二甲氧基聯苯_4_基)丙酸; (S)-2_{[(2-漠-5_氯苯基)曱醯基]胺基卜3_[4,-氰基 ,6、二甲氧基聯苯基]丙酸; (S)-2-{[(2,5-二溴苯基)甲醯基]胺基卜3_[4,-氰基 8 316565 200524846 -2’,6’-一甲氧基聯笨—4-基]丙酸; (S)-2-{[(5-(異丙氧基)_2_溴苯基)甲醯基]胺基卜3_[4,_ 氰基-2’,6’-二甲氧基聯苯_4_基]丙酸 或其醫藥上可接受之衍生物。 本5兒明書之全部内容除非另行說明,否則: 該術語「鹵素」係用於敘述選自氟、氯、溴或碘者; 該術語「Cl_6烷基」係用於敘述由包含1至ό個碳原 子之直鏈或分支狀烷基所組成之基團或基團之一部份;此 等基團之實例包括甲基、乙基、丙基、異丙基、正丁基、 異丁基、第三丁基、戊基或己基; 。亥術π Ci-6烷氧基」係用於敘述以氧原子鍵結至上 述,6烷基之基團或基團之一部份;此等基團之實例包括 :乳基:乙氧基、丙氧基、正丁氧基、異丁氧基、第三丁 乳基、戊氧基或己氧基。 〃本發明化合物之特徵為:於聯苯基核心之4,位置引 氰基並使該聯笨基核心、與所請2,5_二取代苯甲酿基组合 =化合物或其㈣上可接受之衍生物對於經^ …“之細胞黏著具有強烈抑制活性。此外,亦發現 些霄施例於經口投藥及/或適去 極佳生物可利用率。 ^方式全身性投樂後顯現 卜述)展現上述特性之有利組合。 且有=Γ(Ι)化合物或其醫藥上可接受之㈣^ 所有此寺異構型,包括其混合物,皆包含構 316565 9 200524846 非鏡像異構物 法、色層分析法知技術例如··分段結占 型亦可經由下'卞士^ ,凡成。忒化合物之單一立體異構 物製備、或使.由相對應之光學性純之中間產 應消旋物之離析二ριχ =體(=1哪啦由相對 之分段姓曰法制 或、,,工由非鏡像異構物鹽類 之方二曰其中該非鏡像異構物鹽類係由相對庫 =與適當光學活性酸或驗反應形成。或者鏡= 社種二經由與適當對掌性化合物反應形成新共價鍵 =鏡像混合物(在此情況下係分別形成軸類及:〆 二可心^技術如管柱層析法、hplc或分段結晶 本文所使用術語「醫藥上可接受之衍生物」意指林 明化合物之任何醫藥上可接受鹽或前藥例如酯,於投荜至 接受者時,能夠提供(直接或間接地)本發明化合物或^活 性代謝物或殘基。此等衍生物不需經過度實驗而可為該項 技藝中具有通常知識者所辨識。然而,可參照「Burg^,s、 Medicinal Chemistry and Drug Discovery,5th Edition Vol Principles and Practice」之教示,該文教示此類衍生物之 範圍以參考文獻方式納入本文。較佳之醫藥上可接受衍生 物為鹽類及酯類。 ’刀g °接㈣早-種非鏡像異構物可藉由適當化學作用 如新共價鍵之水解分裂而轉換為單—種鏡像異構物。 於有機化學技藝中具有通常知識者應了解,許多有機 化合物可與溶劑形成複合物,其可於溶劑中反應或自溶劑 316565 10 200524846 沉澱或結晶。此等複合物已知為「溶劑合物」。例如,具有 水之複合物已知為「水合物」。本發明化合物之溶劑合物係 包含於本發明之範®壽内。 本文所使用術語「前藥」意指可於體内轉換(例如,藉 由於血液中水解)成為其具有療效之活性形式的化合物。醫 藥上可接受之前藥係詳述於:T· Higuchi and V· Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series,Edward B. Roche,ed·,Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press,1987,and in D. Fleisher, S. Ramon and H. Barbra “ Improved oral drug delivery: solubility limitations overcome by the use of prodrugs” , Advanced Drug Delivery Reviews (1996) 19(2) 115-130,其 中各文獻以參考文獻之方式納入本文。 前藥可為任何經共價鍵結之載劑,當此類前藥經投藥 至病患時,可於活體内釋放式(I)化合物或其醫藥上可接受 之衍生物。前藥一般係經由對官能基進行某種程度之修飾 而製備,因此可藉由例行性操作或於活體内將該修飾裂解 以產生原化合物。於羧酸(-COOH)之實例中,可使用酯類 如曱酯、乙酯、雙酯類等等。酯類可本身具有活性,及/ 或於人體内在活體條件下為可水解性。適當之醫藥上可接 受且於活體内可水解之酯基包括於人體内可輕易分解而留 下原酸(parent acid)或其鹽者。 本發明化合物可呈醫藥上可接受之鹽形式及/或可以 11 316565 200524846 醫藥上可接受之鹽形式投藥。適當鹽類之評介可參見
Berge et al·,J· Pharm· Sci·,1977, 66, 1-19。 '典型地,醫藥上可接受之鹽可使用期望之酸或鹼容易 地製備。該鹽可自溶液沉澱再經由過濾收集或者可經由蒸 發將溶劑移除。 於式⑴化合物之實例中,適當之醫藥上可接受鹽類係 由醫藥上可接受之鹼形成,該醫藥上可接受之鹽類包括銨 鹽類、鹼金屬鹽類如鈉及鉀之鹽類、鹼土金屬鹽類如鈣及 鎂之鹽類以及與有機鹼形成之鹽類,包括一級、二級及三 級月女類如異丙胺、二乙胺、乙醇胺、三曱胺、二環己胺、 N-甲基葡萄糖胺(giucamine)以及參(羥曱基)曱胺。 於其他實施態樣中,本發明亦提供式⑴化合物之製備 方法,該方法包括水解式(II)之羧酸酯衍生物:
R1 、 (II) 及R-係如式(I)中所定義,以及R為可形成羧
(式中R 之基團),之後,視需要可形成其醫藥上可接受之衍生 適當的R基團之實例為Cw烷基如曱基或第三丁基, 316565 12 200524846 較2甲基。水解作用可於酸性或驗性介質中發生。於驗 貝中X解之。兒明貫例為:於適當溶劑中以鹼金屬氫氧 化物處理式(II)化合物,例如於四氮咬喃水溶液中以氯氧化 j處理之。於酸性介質中水解之說明實例為:於適當共溶 J (co_solvent)中、升高之溫度下以無機酸處理式⑴)化合 物例如於一嗜$兀中、6〇c>c下以5N鹽酸處理一夜。此等 方法為該項技藝中具有通常知識者所熟知。 •式(π)化合物可藉由將式(ΙΠ)化合物或其酸加成鹽 (acid addition salt):
(式中R係如式(II)中所定義) 與式(IV)化合物:
(式中R及R-係如式⑴中所定義,以及X為經基或 離去基)反應而製備。
式(III)化合物之酸加成鹽的適當實例為鹽酸鹽。當X 316565 13 200524846 為離去基時,離去基X之適當實例為ii素,較佳為氯。式 (III)與(IV)化合物間之反應,典型係於適當驗例如:有機 驗(如三乙胺)、驗金屬碳酸鹽(如碳酸鋅)或驗金屬碳酸氫鹽 (如碳酸氫鈉)存在下,於惰性有機溶劑如四氫呋喃或二氣 曱烷或混合之有機/水相系統中,以室溫或升高之溫度進 行。當X為羥基時,式(III)與(IV)化合物間之反應係使用 標準耦合方法,例如:使用0-(7-氮雜苯并三唑-1-基)-N,N,N’,N’-四曱基脲鐺六氟磷酸鹽、三乙胺,於無水二曱 基曱醯胺中,於室溫攪拌一夜進行。 實施本發明之最佳模式 式(III)化合物可藉由將式(V)化合物:
(V) 式中Z為離去基,以及Ra為保護基 與式(VI)化合物:
(ho)2b,丫 〇Me (VI) 耦合,接著再將Ra保護基移除而製備。 離去基Z之適當實例為鹵素、烷磺醯氧基(例如:曱 14 316565 200524846 基績酿基)、鹵垸續酿氧基(例如··三氟甲續醒氧基)或芳基 石黃驢氧基(例如:對-甲苯績醒氧基)。保護基之適當實例 包括彼等列於下文者,尤其係第三丁氧基縣(Μ)。 式(111)化σ物亦可藉由將式(V)化合物與式(VH)化合 物 〇Me (VII) (式中Rb為經甲基) 備 耦。接著再移除保濩基Ra並使Rb轉換為氰基而隻 式()化。物與式(VII)化合物間之反應可經 物與_歸物間之反應__。_ 中且古猎由上述方法移除。Rb基團可使用此項技盡 中具有通常知财所熟知或本域収方 : 奶)化,物與式(VI)化合物或式(VII)化合物間之為反:基可 ^例^項技蟄中具有通常知識者所熟知之鈴木輕合 柳ng)條件下進行。經例示說明,該反應可在@ 田 一乙胺)存在時’於升高之溫度下,使 化劑(例如:肆(三笨基膦)絶(0))於適當溶劑(例如甲 -涛各_)中進行。所得產物之保護基可㈣該項技甲藏土 知識者所熟知之方法移除。當保護基為第三; r該去保護作用可藉由在適當溶劑(例如:醇如 316565 15 200524846 乙醇或異丙醇)中以酸處理(例如··鹽酸)而實施。 式(vi)之中間產物化合物可使用上述方法由商業上可 購得之4-溴二甲氧基苯曱酸製得。確信式(11)、(^) 及(VI)之中間產物化合物具有新穎性且可更進一歩形成本 發明之其他實施態樣。 本發明提供式(II)化合物。本發明尤其提供式(11)中R2 為Cl-6院氧基或氟之化合物。 本發明亦提供式(III)化合物或其酸加成鹽。 本發明復提供式(VI)化合物。 中間產物化合物(IV)及(V)亦可自商業上購得或使用 本文所述之方法經由該項技藝中具有通常知識者所知之方 法或其相似方法製備。 。亥項技藝中具有通常知識者應了解,於式⑴化合物或 其醫藥上可接受之衍生物的製備中,其可能必須或期望去 保護該分子中一個或一個以上之敏感基團以避免非期望之 副反應發生。根據本發明所使用之適當保護基係該項技藝 t具有通常知識者所熟知且可用於習知方法者。參見例 如:T.W. Greene 及 P.G.M· Wuts (John Wiley & Sons 1991) 所著之 Protective groups in organic synthesis” 或 P.J.
Kocienski (Georg Thieme Veriag 1994)所著之 “Protecting
Groups 。適當胺基保護基之實例包括:醯基型之保護基 (例如·曱醯基、三氟乙醯基、乙醯基)、芳香族胺基甲酸 醋型之保護基(例如:笨曱氧基羰基(Cbz)以及經取代之 Cbz)、脂族胺基甲酸酯型之保護基(例如··…芴基曱氧基羰 16 316565 200524846 基(Fmoc)、第三丁氧基羰基(Boc)、異丙氧基羰基、環己基 氧基羰基)以及烷基型之保護基(例如··苯曱基、三苯曱基、 氯三苯曱基)。適當氧保護基之實例可包括例如:烷基矽烷 基如三曱基矽烷基或第三丁基二曱基矽烷基;烷基醚類如 四氫吡喃基或第三丁基;或酯類如乙酯。 . 本發明化合物可根據下列分析法進行活體外生物活 性檢驗。
Jurkat J6 親近閃爍測定法(Scintillation Proximity Assay ; SPA ) _
Jurkat J6親近閃爍測定法係用於研究該表現於Jurkat J6細胞膜上之VLA-4與試驗化合物之交互作用。於含有 50 mM HEPES、100 mM NaCl 及 ImM MnCl2(以 4 M Na〇H 將pH調整至7.5)之分析緩衝液中,使J6細胞(1百萬個細 胞/孔)包覆塗覆有麥胚凝集素(wheat germ agglutinin )之 SPA微球(Amersham,1 mg/well)。將氖化之3H標準化合物 A (1至3 nM最終分析濃度)與試驗化合物溶於適當溶劑並· 以分析緩衝液稀釋(最高分析濃度為2.5 μ m ;十點劑量反 應曲線)。重複分析化合物2次並進行四參數曲線迴歸分 析。根據 Cheng & Prusoff (Biochem Pharmacol·,22(23): 3099-3 108 (1973))之方法計算各化合物之平衡解離常數。 數據以平均pKi表示。 標準化合物A為(2S)-3-[4-({[4-(胺基羰基)-1-六氫吡 啶基]羰基}氧基)苯基>2-[((23)-4-曱基-2-{[2-(2-曱基苯氧 基)乙醯基]胺基}戊醯基)胺基]丙酸鉀鹽,其係詳述於專利 17 316565 200524846 氣化之 说明書 WO 00/37444 (Glaxo Group Ltd· et al )中 3H衍生物可使用習知方法製備。 所有根據本發明製備之實例皆可根據此方法進行檢 驗並發現具有pKig 8.6。 从 式(I)化合物或其醫藥上可接受之衍生物會抑制整 合素所媒介之細胞黏著。一般認為α4整合素所媒介之= 胞黏著係與下述範圍内之病症相關,例如:類風濕性關ς 炎(RA);氣喘;過敏症狀如鼻炎;成人呼吸困窘症侯群; 愛滋病失智症;阿茲海默氏症;心血管疾病;血栓或有害鲁 之血小板凝集;再閉塞後之血栓溶解;再灌注傷害;皮声 發炎疾病如乾癖、濕疹、接觸性皮膚炎及異位性皮膚炎: 糖尿病(例如··胰島素依賴型糖尿病、自體免疫性糖尿病); 多發性硬化症;全身性紅斑性狼瘡(SLE);發炎性腸道疾病 如潰瘍性結腸炎、克隆氏症(局部性腸炎)及迴腸囊袋炎 (pouchitis)(例如:於直腸大腸切除術或迴腸肛門吻合術後 所產生),與白血球浸潤至腸胃道有關之疾病如乳糜瀉、非· 熱帶口炎性腹瀉(nontropical sprue)、與血清陰性關節病變 有關之腸病變、淋巴球性或膠原性結腸炎及嗜伊紅血球性 月腸炎,與白血球浸潤至其他上皮内襯組織(epithelial lined tissues)如皮膚、泌尿道、呼吸道及關節滑膜有關之 疾病;胰臟炎;乳房炎(乳腺);肝炎;膽囊炎;膽管炎或 膽管周圍炎(肝臟中之膽管及周圍組織);支氣管炎;鼻竇 炎、肺臟發炎疾病所導致之間質纖維化如過敏性肺炎;膠 原疾病(於SLE及RA);類肉瘤病;骨質疏鬆症;骨關節 18 316565 200524846 炎;動脈粥樣硬化;腫瘤性疾病包括惡性腫瘤之轉移或癌 之增生’創傷(促進創傷癒合特定眼疾如視網膜剝離、 過敏性結膜炎及自體免疫性葡萄膜炎;修格連氏症候群 (Sjogren’s syndrome);器官移植後之排斥作用(慢性或急 性);宿主對移植物或移植物對宿主疾病;内膜增生;動脈 硬化(包括移植後之移植物動脈硬化);手術後如經皮冠狀 動脈氣球擴張術(percutaneous transluminal angioplasty,PTC A)及經皮冠狀動脈再開通(percutane〇us tranSlUminal artery recanalizati〇n)後之再栓塞或再狹窄;腎 φ 炎;腫瘤血管新生;惡性腫瘤;多發性骨髓瘤及骨髓瘤所 誘導之骨溶蝕作用(boneresorpti〇n);敗血症;以及中枢神 經系統損傷如中風、創傷性腦損傷及脊髓損傷與梅尼爾氏 症(Meniere’s disease)。 本發明化合物較佳可用於治療或預防氣喘、過敏症狀 如鼻火、發炎性腸道疾病如潰瘍性結腸炎及克隆氏症、類 風濕性關節炎、異位性皮膚炎、多發性硬化症及器官移植 後之排斥作用。尤其,本發明化合物可用於治療或預防發 炎性%道疾病或多發性硬化症。 本發明更進一步提供以媒介細胞黏著之α 4整合素的 抑制劑處理可發揮效益之疾病 < 治療或預防方法,該方法 包括.將安全及有$欠量之式⑴化合物或其醫藥上可接受之 衍生物投藥至需要此治療之病患。本發明尤其提供治療或 預防上述病症之方法。 本毛月亦提供用於治療(.尤其係用於治療或預防上述 316565 19 200524846 病症)之式(i)化合物或其醫藥上可接受之衍生物。 於另一實施態樣中,本發明提供式⑴化合物或其醫華 上可接受之衍生物於藥劑製造上之用途,該藥劑係用於治 療或預防以媒介細胞黏著整合素的抑制劑處理能發 揮效益之病症,尤其係上述之病症。 雖=發明化合物可經單獨投藥,但其較佳係根據標 法配製為醫藥組成物。因此本發明亦提供包括 =有效虿之式⑴化合物或其醫藥上可接受之衍生物與 …可接受之載劑或稀釋劑混合之醫藥組成物。 、◊本發明進一步提供包括式⑴化合物或其醫藥上可接 又之何生物以及另—種治療活性劑之醫藥組成物。 本發明更進一步提供製備醫藥組成物之方法, 匕括將至少—種本發明化合物或其醫藥上 :/ 與醫藥上可接受之載劑或稀釋劑混合。 又何物 該醫藥組成物可於人類或獸醫藥物中供 使用’且係典型地包含任何一種或一種以上之醫= 灣劑、載劑或賦形劑。作為治療用途之可接:可接 稀釋劑為製藥技藝中所熟知,且係詳述於例如汉又載劑或 Pharmaceutical Sciences, Mack Publishing C〇 (A lngt〇n '
Gennar°edlt· 1985)。醫藥上可接受之載劑、賦开卜,. f之選擇可根據所欲之投藥途徑或標準製藥=或稀釋 遗。該載劑或稀釋劑必須為醫藥上可接、二進订師 接叉者而言應為無毒性。該醫藥上可接受之=p對於其 可為例如:黏結_如糖聚、阿拉 ^或賦形劑 月.、山梨醇、 3】6565 20 200524846 西只蓍膠、聚乙婦基Dft㈣_)、 玉米殺粉、她η梨醇、甘胺酸隸、薦糖、 酸鎂、滑石、聚乙二醇、石夕石 月劑(例如硬脂 濕潤劑(例如硫酸月桂醋納)等等:以(例如馬鈴薯激粉)、 本發明組成物之投藥(投遞) 種或-種以上之方式··經σ投羊(例如限於下列-« t (例如作為錠劑、膠嚢或可 攝取之溶液)、局部投藥、經黏膜 /囊戍了 ^ 95 Λ ^ ^ . 仅去(例如作為鼻用喷劑 或及入之_)、經鼻投藥、_投藥(例如經由可注 射型式)、經腸胃投藥、脊髓内投 允机嚅^ , 腹艇腔内投藥、肌肉 才又k、砰脈内投藥、子宮内投藥、眼内投藥、皮内投μ、 腦内投藥、氣管内投藥、陰道内投藥、腦室内投藥、:腦 内,藥、皮下投藥、經眼投藥(包括玻璃體内(imravitreai) 投樂或脈絡膜内(illtraCameral)投藥)、經皮投藥、直腸投 藥、口腔投藥、經硬脊髓膜外腔投藥、舌下投藥。又 例如,该化合物可以下列形式經口投藥:錠劑、膠囊、 粒劑、酏劑、溶液或懸浮液(其可包含調味劑或著色劑^ 以提供直接_、延遲-、修飾-、持續…脈衝-或控制型-釋放 之施用。該錠劑可包含賦形劑如微晶纖維素、乳糖、擰檬 酸納、碳酸鈣、磷酸氫鈣及甘胺酸;崩解劑如澱粉(較佳為 玉米、馬鈴薯或樹薯澱粉)、羥乙酸澱粉鈉、交聯竣甲基纖 維素鈉(croscarmellose sodium)及某些複合石夕酸鹽類;以及 制粒黏結劑如聚乙烯基D比洛烧酮、羥丙基曱基纖維素 (HPMC)、羥丙基纖維素(HPC)、蔗糖、明膠及阿拉伯膠。 此外,復可包含潤滑劑如硬脂酸鎂、硬脂酸、山窬酸甘油 21 316565 200524846 酯及滑石。相似類型之固體組成物亦可作為明膠膠囊之殖 (miIk sugar)或高分子量聚乙二醇。對於水性縣浮 句相味劑、著色劍或 木枓料化獻/或懸浮劑以及稀釋劑如水、乙醇 醇及甘油、以及其之組合合用。 一 本發明化合物可經使用習知研磨方法如濕磨法㈣ mdlmg)研磨以得到適用於錠劑或其他劑型之粒子 發明化合物經精細分割(奈米粒子)之製劑可藉由該項技藝 中已知之方法製備,例如參見國際專利申請書第㈣ 02/00196 號案(SmithKline Beecham)。 右本土明化合物為非經腸投藥,則此等投藥法之實例 係包括下歹:卜種或-種以上之方式··經靜脈内、動脈内、 、 _⑹至内、尿這内、胸骨内、顧内、肌肉 内或皮下技與该樂劑;及/或藉由使用輸液技術投荜。對非 經腸投藥法而言,該化合物最佳係以無g水溶液形式使 用、,其可包含其他物質例如:足夠之鹽類或葡萄糖,以使 血液等張。若需要,應將該水溶液適當地緩衝化 (pH自3至9較佳)。該於無菌狀態下之適當非經腸調配物 衣η丨可以。玄項技蟄中具有通常知識者所熟知之標準製藥技 術輕易完成。 士所不本發明化合物可經鼻或藉由吸入方式投藥, 且线㈣當推進劑例如:二氣二敗甲炫、三氣說甲烧、 氣四氟乙:):凡、氫敗烧如Up—四氣乙烧⑽A IB ΑΤ”,,) 22 316565 200524846 或 1,1,1,2,3,3,3-七氟丙烷(HFA 227EA)(例如來自 Ine〇s
Fluor) 一氧化碳或其他適當氣體,由加塵之容哭、戈 喷霧器或霧化器,以乾粉吸入劑型或氣霧噴霧劑形式適當 地投與。就加壓之氣霧劑而言,該劑量單位可藉由下述方 式決定:提供閥以投遞計量供給之量。該加壓之容器、泵、 喷霧器或霧化器可含有活性化合物之溶液或懸浮液,例 如.使用乙醇與該推進劑之混合物作為溶劑,其可同時包 =潤滑劑例如山梨糖醇酐三油酸酯。使用於吸入器或:: 器之膠囊及膠粒(例如:由明膠製造)可調配成含有化合物 與適當粉末基質(如乳糖或澱粉)之粉末混合物。 或者,本發明化合物可以栓劑或子宮托形式投藥, 其可以凝膠、水凝膠、洗劑、溶液、乳膏、軟膏或敷粉形 式局。Me用。本發明化合物亦可藉由例如使用皮膚貼布而 經皮或穿透皮膚投藥。其亦可經由肺部或直腸途徑投雄。 其亦可經由眼部投藥。為使用於眼部,該化合物可於等"張、 PH經调整之無菌鹽水中調配為微粒化懸浮液,或較佳於等 張:PH經調整之無菌鹽水中調配為溶液,且視需要可與保 存劑如氣化苯二曱經錢(benzylalk〇niumchi〇dde)組合。 或者,其可經调配為軟膏如凡士林。 、為局部施用於皮膚,本發明製劑可經調配為含有將該 活卜生化合物>予或溶解於例如具有下列一者或一者以上之 混合物中的適當軟膏:礦物油、液態石瑕、白凡士林、丙 7酵、氧伸乙基系聚合物-氡伸丙基系聚合物、乳化蠟及 水。或者’可將其調配為適當洗劑或乳膏,經懸浮或溶解 23 316565 200524846 於例如下列一者或一者以上之混合物中 酐單硬脂酸酯、聚乙二醇、、夜能 ", 木-子 ^ 液心石4鼠、聚山梨醇酐脂肪酸 W〇、㈣㈣、综櫚醇、2 —辛基十二院醇、苯甲醇及水。 本發明之組成物可藉由直接注射而投筚。 於較佳具體實施例中’本發明之製劑係經全身性投遞 (如經口服、經口腔、經舌下),更佳者為經口服。 口此較乜者仏5亥製劑為適用於口服投遞之型式。 旦=型地,將由醫師決定該最適於個別接受者之實際劑 里。用於任何特定個妙夕枯—令丨曰 ▲ 彳寸疋劑I》辰度及劑量頻率可依據 ° m ’該因子包括:所使用之特定化合物的 / 化合物之代謝穩定性及作料間、年齡、體重、 ::健康狀況、性別、飲食、投藥模式及時間、排泄速率、 組合、特定病症之嚴重程度以及個別接受之治療。 對於經由口或非經腸投藥至人類而言,該製劑之每日 劑置可以單一劑或分成數劑投與。 根據本發明,該化合物投藥至人類(體重大約7〇kg)之 建議劑量為:每單位劑量0._至2§,較佳為〇1叫至 k之活性成分,其係以游離酸之重量表示。該 日,投與例如…次。該劑量係取決於投藥途徑。當二 ^可月b而要依病患之年齡、體重及病症嚴重程度對劑量進 订例订性變化。該劑量亦取決於投藥途徑。該精確劑量及 投藥途徑最終將由巡診醫師及獸醫決定。 本發明化合物亦可與其他治劑組合使用。因此,於其 他只知悲I中本發明係提供包括本發明化合物或其醫藥上 3]6565 24 200524846 可接文之衍生物與其他治療劑之組合。 當式(I)化合物或其醫藥上可接受 2療劑(對於相同疾病狀態具有活性)組合使用時^ ::劑量:能與單獨使用該化合物時不同。適當之; 化::技蟄中具有通常知識者輕易領會。經了解,本發明 化合物於治療或子音P六卜 年Mi广此置可依疾病之性質以及病患之 ^與症狀而改變’且最㈣由診察f師及獸醫決定。可
性:(二合物或其醫藥上可接受之衍生物組合的其他活 性衣劑貫例包括,但不限於:(a)其他VLA 織胺拮抗劑;⑷則D,s;⑷抗糖尿病劑,例如格: 讀(_a驗s)藥物;⑷抗膽驗劑;(f)c〇x_2抑制劑, 例如2-(4-乙氧基-苯基)_3_(4_甲續酸基-苯基吼唾并 。荅哄(如專利申請案W0 99/1293〇中所揭露);(g)pDE_iv 抑制劑;(h)類固醇,例如皮質類固醇;(猶效 趨化細胞激素f體拮抗劑,例如CCR_2、ccr_3、 及CCR 8 ’ (k)適當之多發性硬化症治療或預防如干擾素; ⑴LFA]拮抗劑;㈣TNF抑制劑;⑻柳氮磺胺呲啶…’ (smpha—ne )及5_胺基水楊酸鹽;以及(。)免疫抑制劑。 上文所提及之組合可為醫藥調配物之形式,因此包含 j述所定義之組合以及醫藥上可接受之載劑或賦形劑的醫 藥調配物係本發明之另一態樣。此等組合之個別成分可經 由任何方便的途徑,以分開或組合之醫藥調配物相繼地Z 同時地投藥。若為相繼投藥時,可先投與本發明化合物或 該第二種治療劑。若為同時投藥時’該組合物可以相同或 316565 25 200524846 相異之醫藥組成物投藥。 、將兩種化合物組合於相同調配物中,則應了解該 2種化合物必須穩定且彼此相容並與其他調配物之成分相 谷。經個別調配時,等化合物可便利地以該項技藝中已知 之方法以任何適宜之調配物提供。 本況明書中所引用之所有刊物(包括但不限於專利及 專利申明案)以麥考文獻方式納入本文,如同各個別刊物 在本文中被個別指定全文做為參考文獻一樣。 【實施方式】 下列製備例及實施例係說明本發明化合物之製備。 一般方法 ,於實驗章節所示之術語MDAP表示質譜指引之自動 衣備法(Mass Directed Auto Preparation),係藉由製備型 hplc將化合物純化之自動化系統,並藉由將質譜儀與製 備型HPLC系統組合,以偵測及收集具有所期望質量之部 刀接著,再使用Waters FractionLynx MADP系統以及適 當之逆相層析管柱,該逆相層析管柱係使用水/乙腈梯度溶 析,且兩種溶劑皆含〇. 1%曱酸。 製備例1 (S)-2-第二丁氧基羰基胺基_3_(4_羥基苯基)丙酸曱酯(ρι) 將二碳酸二-第三丁酯(200 g,〇 92 m〇1)分批加至^酪 胺酸曱酯鹽酸鹽(200 g,〇·86 m〇1,Aldnch)與碳酸氫鈉(1〇〇 §,1.19 111〇1)之二氯曱烷(11〇及水(1][〇混合物中。於室溫下 攪拌該混合物2小時。分離有機層並使用二氯曱烷(5〇〇 mi) 316565 26 200524846 再萃取水層。將合併之有機層以硫酸鎂脫水、過濾並減壓 濃縮以產生如無色玻璃之粗標題化合物,其係未經純化而 用於後續步驟;LC/MS (ES-ve) : [M-Η]· at m/z 294 (C15H2iN05 之理論值:[M-H]-atm/z 294)。 製備例2 (S)-2-第二丁氧基幾基胺基_3-(4-三氟甲續醢基氧基苯基) 丙酸甲酯(P2) 於氬氣下’將D比咬(58 mL,0.72 mol)添加至粗(S)-2-第 二丁氧基羰基胺基-3-(4-羥基苯基)丙酸曱酯(pi,70.5 g, 0.24 mol)之二氯曱烷(1L)溶液中。使該溶液於冰中冷卻, 接著再滴加三氟曱磺酸酐(52 mL,0.31 mol)並同時攪拌 之。於添加完成後,將該混合物於冰中攪拌2小時、以2M 鹽酸(500 mL)洗滌、經硫酸鎂脫水、過濾並減壓濃縮。粗 產物經石夕膠管柱層析法(Bi〇tage 75L,800g石夕石)純化,以 乙酸乙酯:己烧(15:85)沖提,產生無色油狀之標題化合物, 其緩慢固化’得到白色固體;LC/MS (ES+ve): [M-BOC+H] + at m/z 328 (C16H20N〇7 之理論值:[m+H]+ at m/z 428)。 製備例3 4笔曱基2,6-—曱氧基笨基硼酸(P3) (ps :卿酸:boronic acid) 於氬氣下’將(3,5-二甲氧基苯基)曱醇(53 g,0.31 mol, Aldnch)之無水四氫呋喃(1L)溶液冷卻至-50°C至-70°C,並 使用正丁基鐘(45〇 mL,1·6Μ於己烧,0.72 mol)處理30分 鐘。於添加後’以45分鐘時間使該反應混合物升溫至〇°C, 27 316565 200524846 接著於室溫下靜置2小時。而後將該反應液再冷卻至, c並以删酸二甲s旨(135 mL,115 mQl)分次處理之。於添加 後,使該混合物升溫至室溫並另外攪拌18小時。該反應係 方、〇 C下經由分批添加擰檬酸水溶液(75 g檸檬酸於 mL水中)而終止。添加氣化鈉使水層飽和並以乙酸乙酯(2 X 1L)萃取該產物。使合併之有機層經硫酸鎂乾燥、過濾並 減壓濃縮。將乙酸乙酉旨添加至殘餘物,過遽收集所得益色 沉澱並於4(TC下真空乾燥以產生無色固體之標題化合 物,其係未經純化而用於後續反應。 製備例4 (S)-2-第二丁氧基羰基胺基_3_(4,_羥甲基_2,,6,_二甲氧基 聯苯-4-基)丙酸甲酯(p4) 將二乙胺(28 mL,0.20 mol)添加至(s)_2_第三丁氧基 羰基胺基-3-(4-三氟甲磺醯氧基苯基)丙酸甲酯(p2, 42 73匕 0.10 _1)及4-經曱基_2,6_二甲氧基苯基硼酸(p3, 29 7匕 〇.14mol)之無水二甲基甲醯胺(25〇mL)溶液中。於使用氬 除氣後,添加肆(三苯基膦)鈀(〇)(58^5111111〇1),並於氬 氣下將該混合物加熱至9(TC1小時。[觀察到NB a輕微放 熱]。在使其冷卻至室溫後,以乙酸乙醋(1 L)及水(7〇〇 mL) 稀釋該混合物’並分離之。將有機層以水(2 χ 3〇〇叫洗 滌、經硫酸鎂脫水、過濾並減壓濃縮。粗產物經矽膠管柱 層析法(Biotage 75L,800g矽石)純化,以乙酸乙酯:己烷 (50.50)冲提,產生無色固體之標題化合物; (ES+ve) : [M_B0C+H]+ at m/z 346 (C24H3iN〇7 理論值 316565 28 200524846 [M+H]+ at m/z 446)。 製備例5 (S)-2-第三丁氧基羰基胺基-3-(4,-曱醯基-2,,6,-二甲氧基 聯苯-4-基)丙酸甲酯(P5)
將二氧化猛(230 g,2.64 mol)分批添加至(S)-2-第三丁 氧基羰基胺基-3-(4’-羥甲基_2’,6、二甲氧基聯苯基)丙 酸曱酯(P4, 28.98 g,65.1 mmol)之二氯曱烷(1 L)溶液中。使 所付懸洋液於室溫下撲掉1小時’接著通過石夕藻土過遽, 再以一氯曱烧(1 L)洗蘇該石夕藻土墊。減壓濃縮遽液以產生鲁 無色泡沫之產物,其係未經近一步純化而供使用之;LC/MS (ES+ve) : [M-BOC+H]+ at m/z 344 (C24H29N07 理論值 [M+H]+ at m/z 444)。 製備例6 (S)-2-第三丁氧基羰基胺基_3_[4,_(羥亞胺基甲基>2,,6,_二 甲氧基聯苯-4-基]丙酸曱酯(P6) 將鹽酸經胺(7.4 g,106 mmol)及二異丙基乙胺(1 8 mL, 106 mmol)添加至(S)-2-第三丁氧基羰基胺基-3-(4,-曱醯基 β -2,6 -一曱氧基聯苯_4_基)丙酸曱g旨(ρ5,23.6 g,53 mmol) 之四氫呋喃(300 mL)溶液中。使該反應混合物回流加熱2 小時’接著再冷卻至室溫。減壓濃縮該溶液,而後再溶解 於乙酸乙酯中(500 mL),以10%檸檬醪水溶液、水、以及 鹽水(各500 mL)洗滌,經硫酸鎂乾燥,過濾並減壓濃縮以 產生無色泡沫,其係未經進一步純化而用於下一步驟; LC/MS (ES+ve) : [M-BOC+H]+ at m/z 359 (C24H30N2〇7 理 29 316565 200524846 論值[M+H]+ at m/z 459)。 製備例7 (S)-2-胺基-3_(4’-氰基)-2,,6,-二甲氧基聯苯基基】丙酸甲 酯鹽酸鹽(P7) 於〇°C、氬氣下將氣化亞硫醯(3〇 mL,411 mmol)滴加 至(S)-2-第三丁氧基羰基胺基羥亞胺基曱基>2,,6,_ 二曱氧基聯笨基]丙酸曱酯(P6, 46」g,ιοί mmol)之二氯 曱烧(500 mL)溶液中。使該反應液升溫至室溫並授拌3 天。過遽收集沉澱之固體,以二氣甲烷(2〇〇 mL)洗滌並於 45 C減壓乾燥。單離該標題化合物,其呈白色固體;lc/ms at m/z 341)。 製備例8 2-溴-5-經基苯甲酸甲酯(p8) 於氬氣下攪拌含2-溴-5-甲氧基苯曱酸(3〇.〇 g,13〇 mmol,Aldrich)之無水二氯曱烷(6〇〇 mL),並於乾冰/丙酮 中冷卻,以1 5分鐘時間添加三溴化硼μ於二氯甲烧,28〇 mL,280 mmol)。接著將該混合物於室溫下攪拌2 5小時, 產生沉殿。而後以3 0分鐘時間謹慎地滴加曱醇(3〇〇 mL) (注意··起始時為強烈放熱並伴隨起泡),最後得到深色均 貝/谷液,並於§亥溶液中添加濃硫酸(1 5 mL)。使溶液回流攪 拌1小時、冷卻之、並減壓濃縮。將殘餘物溶於二氯甲烷 (500 mL)中、以鹽水(5〇〇 mL)洗滌、經硫酸鎂乾燥、過濾 並減壓濃縮以產生固體標題化合物;LC/MS (ES+ve): 30 316565 200524846 [M + H]+atm/z231,233 (C8H7Br〇3 理論值[M + H]+atm/z 231, 233)。 製備例9 2-溴-5-乙氧基苯甲酸曱酯(P9) 於氬氣下攪拌含氫化鈉(60%於礦物油中,4.24 g,106 mmol)之無水二曱基曱醯胺(150 mL),並於冰中冷卻,以 15分鐘時間添加含2-溴-5-羥基苯甲酸甲酯(P8, 20.41 g5 88 mmol)之二曱基甲醯胺(150 mL)。使該混合物於室溫下攪拌 45分鐘,於冰中再冷卻,並以蛾乙烧(8.5 mL,106 mmol) 處理之。將此混合物於室溫下攪拌3小時、減壓濃縮、以 乙酸乙酯(400 mL)稀釋、再以水(3 X 400 mL)及鹽水(400 mL)洗滌、並經硫酸鎂脫水、過濾以及減壓濃縮,產生標 題化合物,其係受微量之對應乙酯以及殘餘礦物油污染。 此物質係未經進一步純化而用於下一步驟;LC/MS (ES+ve) : [M+H]+ at m/z 259, 261 ((:10比而〇3 理論值 [M+H]+ at m/z 259, 261) 〇 製備例10 2-溴-5-乙氧基苯甲酸(P10) 將2-溴-5-乙氧基苯甲酸曱酯(P9, 20.53 g,79 mmol)置 於四氫呋喃(600 mL)中攪拌,並以含有氫氧化鋰(18.2g, 79 1 mmol)之水(200 mL)處理。使該混合物檟:拌4天、減壓 濃縮、以水(500 mL)稀釋、再以5N鹽酸酸化並萃取至乙 酸乙酯(2 X 300 mL)中。將合併之萃取液以鹽水(250 mL) 洗滌、經硫酸鎂脫水、過濾並減壓濃縮以得到灰白色固體。 31 316565 200524846 與己烧一起濕磨、過濾、以及乾燥,得到白色粉末之標題化 合物;LC/MS (ES+ve) : [M+H]+ at m/z 245, 247 (C9H9Br03 理論值[M+H]+atm/z 245,247)。 製備例Π (8)-2-{[1-(2-溴-5-乙氧基苯基)曱醯基】胺基卜3_(4,_氰基 -2’,6’-二曱氧基聯苯-4-基)丙酸甲酯鹽酸鹽(pi 於JL氣下將(S)-2-胺基-3-(4、氰基)-2’,6’-二曱氧基聯 苯-4-基]丙酸甲酯鹽酸鹽(P7, 37.1 g,98.5 mmol)溶於二氣 甲烷(500 mL)及水(400 mL)中,並冷卻至〇°c。添加碳酸氫_ 鈉(20.1 g,239.3 mmol)至該反應混合物中,接著再滴加2-溴-5-乙氧基苯曱醯氯(27.2 g,103.7 mmol){係使用草醯氣 (4當量)’在二氣曱烧及一滴二曱基曱酸胺中,經由標準方 法自2-溴-5-乙氧基苯甲酸(P10)製備}。使該反應物於〇。〇 下攪拌1小時,接著再以飽和碳酸氫鈉水溶液(2〇〇 mL)稀 釋。於有機層分離後,使用二氯曱烷(2 X 400 mL)再萃取 水層。將合併之有機層以硫酸鎂乾燥、過濾並減壓濃縮。_ 產物經石夕膠管柱層析法(Biotage 75L,800g石夕石)純化,以 乙酸乙_ :一氣曱烧(3:97)沖提,產生無色固體之標題化合 物;MS (ES+ve): [M+H]+ at m/z 567,569 (C28H27BrN206 理 論值[M+H]+ at m/z 567, 569)。 製備例12 (S)-2-{[l-(2-溴-5-甲氧基苯基)甲醢基]胺基卜3-(4,_氰基 _2’,6’_二曱氧基聯苯基-4-基)丙酸乙g旨(P12) 於氬氣、室溫下,將2-溴-5-甲氧基苯曱酸(0.355 g, 32 316565 200524846 1.54 mmol,Aldnch)、0-(7-氮雜苯并三唑_^)·ν,ν,ν,,ν,、 四曱基脲鍚六氟磷酸鹽(Μ68 g,2當量)以及三乙胺(1069 mL,5當里)添加至一曱基曱酿胺(25 mL),同時攪拌之。於 〇·5小時後,添加該與P7相對應之乙酯(pi3) : (s)_孓胺基 -3-(4’-氰基-2’,6’-二曱氧基聯苯-4-基)丙酸乙酯鹽酸鹽(〇 6 g,1 ¥里),並持續稅拌一仪。接著減壓蒸發溶劑並將殘餘 物分溶於乙酸乙酯與水之間。於蒸發至乾前,以水(χ2) 及飽和碳酸氫鈉水溶液洗滌有機層。粗產物係藉由矽膠管 柱層析法純化,其中使用〇至10%甲醇二氣曱烷梯度層 析’接著再經製備型HPLC純化,得到標題化合物。 MS (AP+ve): [M+H]+ at m/z 567, 569 (C28H27BrN206 理論值[M+H]+atm/z 567,569)。 製備例13 (S)-2-胺基-3-(4’-氰基-2’,6’-二甲氧基聯苯_4_基)丙酸乙酯 鹽酸鹽(P7-對應乙酯)(pi3) 於〇°C、氬氣下,以15分鐘時間將氣化亞硫醯(7 71 mL, 105.7 mmol)滴加至(S)-2-第三丁氧基羰基胺基_3_[4,_(羥亞 胺基甲基)-2’,6、二甲氧基聯苯_4_基]丙酸乙酯(12.5g,26.5 mmol)[係以相似於p 1至p6之順序製備,不過於製備例j 開始時以L-赂胺酸乙酯鹽酸鹽(得自Bachem)取代L-酪胺 酸曱酯鹽酸鹽]之二氣甲烷(250 mL)溶液中。使該反應於批 次溫度下再攪拌15分鐘,然後升溫至室溫並持續攪拌一 夜。過濾收集沉澱之標題化合物,以二氣曱烷(2χ15 mL) 洗滌並減壓乾燥。LC/MS (ES+ve) : [M+H]+ at m/z 355 33 316565 200524846 (C20H22N2O4 理論值[M+H]+atm/z 355)。 實施例1 (S)-2-{[l-(2-溴-5-乙氧基苯基)曱醢基]胺基卜3-(4,-氣基 -2’,6’-二曱氧基聯笨-4-基)丙酸(E1)
將(S)-2-{[l-(2-溴-5-乙氧基苯基)甲醯基]胺基卜3-(4,_ 氰基二甲氧基聯笨-4-基)丙酸曱酯(Pll,51.5g,90.8 mmol)之四氫呋喃(950 mL)溶液冷卻至〇°C並以0.5 Μ氫氧 化鋰水溶液(700 mL)處理之。使該反應混合物於〇°c授拌1 小時’接著再以5 Μ鹽酸酸化。於真空下蒸發四氫咲喃並 將殘餘物以乙酸乙酯稀釋。於分離有機層後,以乙酸乙酯 再萃取水層。將合併之有機層以水(Χ2)洗滌再經硫酸鎂乾 燥,並於真空下蒸發溶劑以產生無色固體之標題化合物; 1H NMR δ (DMSO-d6): 1.29 (3H, t, J7.0Hz), 2.96 (1H, dd, J 13.9, 10.9Hz), 3.22 (1H, dd, J14.1, 4.2Hz), 3.71 (6H, s), 3.99 (2H, q, J7.0Hz)t 4.65 (1H, ddd, J10.9, 8.4, 4.3Hz), 6.69 (1H, d, J3.0Hz), 6.91 (1H, dd, J8.8, 3.1Hz), 7.14 (2H, d, J8.1Hz), 7.24 (2H, s), 7.32 (2H, d, J8.1Hz,)t 7.47 (1H, d, J8.8Hz), 8.77 (1H, br. d, J8.4Hz), 12.83 (1H, br. s); MS (ES+ve) [M+H] at m/z 553, 555 (〇27Η25Β「Ν2〇6 requires [M+H]+ at m/z 553, 555). 實施例1-替代合成方法 該標題化合物亦可使用下列方法製備。 4-溴-3,5-二曱氧基苯曱醯胺 34 316565 200524846 將氯化亞硫酿(60 mL,0.82 mo])添加至經授拌之4-漠 -3,5-二曱氧基苯甲酸(得自 Jmtan Baocheng,100 g,0.38 mol)的甲苯(700 mL)及二曱基甲醯胺(1 mL)懸浮液。於氮 氣下回流攪拌該反應物。2小時後HPLC顯示酸完全耗盡, 得到曱醋(酸氣化物用曱醇使之停止反應)。蒸餾移除揮發 物並將所得固體添加至0.88氨(350 mL)。使該混合物於室 溫下攪拌45分鐘。過濾產物,以水(2 X 200 mL)洗滌並於 真空下乾燥一夜以產生灰白色固體之標題化合物 1H NMR δ (DMSO-d6): 3.89 (6H, s), 7.23 (2H, s), 7.52 (1H, s), 8.2 (1H, s) MS (ES+ve) [M+H]+ at m/z 260, 262 (C9H10B「N〇3 requires [M+H]+ at m/z 260, 262) 4-溴-3,5-二甲氧基苯甲腈 將三氯乙酸酐(129 mL,0.91 mol)添加至4-溴-3,5-二 甲氧基苯曱醯胺(104 g,0.3 8 mol)之吡啶(127 mL,1.57 mol) 及四氳呋喃(950 mL)懸浮液中。使用冰浴將溫度維持在20 至25°C。於氮氣下,使該橙/棕色溶液於20至25°C攪拌1 小時。HPLC顯示4-溴-3,5-二曱氧基苯曱醯胺完全耗盡以 得到產物。將反應混合物濃縮至大約起始體積之50%。添 加水(900 mL)並濾除產物、以水(2 X 250 mL)洗滌並於40 QC下真空乾燥以產生鬆軟灰白色固體之標題化合物。 1H NMR δ (CDCI3): 3.96 (6H, s), 6.8 (2H, s) 4-氰基-2,6-二甲氧基苯基腼酸(口8:腼酸:1}〇1*01^&(^(!) 於5至10°C、氮氣下,將異丙基鎂氣化物(isopropyl magnesium chloride)(於四氫咲喃之 2M 溶液,206 mL, 0.412 mol)添加至4_溴-3,5-二曱氧基苯甲腈(50 g,0.207 35 316565 200524846 ^ 氫夫南(400 mL)漿狀物。使所得溶液升溫至室 、,、HPLC刀析顯示起始原料已完全消耗。將反應混合物 冷卻至5 $ 1 A 、,、 斤 C,並添加至硼酸三甲酯〇〇3 mL,0.92 mol) 氫夫南(100 mL)溶液,添加期間係將溫度維持在1〇。〇 ,下=反應升溫至室溫。HpLC顯示產物反應完成。將 乂反二作匕a物冷部至5至1〇〇c並添加鹽酸(別〇 mL), 4加期間h將溫度維持纟i 〇。〇以下。力室溫搜摔該混合物 3〇分鐘,接著蒸餾移除揮發物。過濾產物、以水洗滌之並 於40 C真空乾燥以產生灰白色固體之標題化合物。 1H NMR δ (DMSO-de): 3.78 (6H, s), 7.0 (2H, s), 9.25 (2H, s) (S)-2-胺基-3-(4,-氰基-2,,6,_二甲氧基聯苯_心基)丙酸甲酯 鹽酸鹽 於90t下將二碳酸二-第三丁酯(17 9 g,81 8 mm〇1)i 曱苯(60 mL)溶液滴加至⑻_甲基酪胺酸(得自Flamma, 15·2 g,77.9 mmol)之甲苯(120 mL)溶液。使該反應混合物 於90 C攪拌至少30分鐘。一旦經HPLC分析完成,將該 反應混合物冷卻至〇°C並添加吼唆(19 mL,0.23 mol)(溫度 維持於0°C)。滴加三氟甲烷磺酸酐(16.7 mL)(溫度維持於 〇°C)。將該橙色漿狀物於0°C下攪拌至少2小時。一旦經 HPLC分析完成,添加2M鹽酸(133 mL)(溫度維持於〇 °C )。將各層分離並以10% w/w碳酸鈉水溶液(138 mL)及 36% w/w鹽水(13 8 mL)洗滌上層有機層。有機層經濃縮為 大約60 mL並先後添加固態氣化鈉(30 g)及正庚烧(3〇〇 mL)。將混合物過濾,並使濾液萃取至1 -甲基-2-D比α各坑酉同 36 316565 200524846 (2 X 1 50 niL)。於真空下蒸餾殘餘之揮發性有機溶劑。添 加4-氰基-2,6-二曱氧基苯基硼酸(17·5 g,84·5 mm〇i)並將 違溶液除氣。添加肆(三笨基膦)把(〇)(38,2.7111111〇1)及三 乙胺(19.8 mL) ’並使該反應混合物加熱至7〇它。於7〇。〇 下攪拌該反應物至少2小時。一旦經HPLC分析完成,將 反應混合物置換至另一個容器並以甲苯(3〇〇 mL)稀釋。添 加2M鹽酸(3 00 mL)並過渡該混合物。將有機層分離並以 水(300 mL)洗滌。過濾有機層並以甲苯(9〇 mL)洗滌。使該 甲苯溶液與以Silicycle矽石支承之N_官能化硫脲(11.7 g) 攪拌至少15小時。過濾該矽石並以曱苯(3〇 mL)洗滌。將 該溶液共沸乾燥,接著再於5(TC下緩慢添加至氣化氫之異 丙醇(155 mL, 5M濃度)溶液。使反應混合物於5(rc下攪拌 3〇分鐘直至經HPLC分析完成。將混合物冷卻至2〇〇c並於 真空下濾、除產物’再以曱苯(60 mL)洗蘇之。使該固體於 40 C真空乾燥以產生灰白色固體之標題化合物。 2-溴-5-羥基苯甲酸甲酯 於-15至-10 C下將二 >臭化石朋(18 mL,190.5 mmol)之二 氯甲烧(1 8 mL)溶液添加至經攪拌之2-溴-5-甲氧基苯曱酸 (得自 Wychem,20 g,86.6 mmol)的二氯甲烷(200 mL)懸浮 液。使該黃色懸浮液升溫至〇°C。HPLC分析顯示酸已耗 趾。添加甲醇(100 mL)使反應終止。將該澄清深色溶液回 流授拌(大約45°C )12小時,蒸發至乾,分溶於水(4〇〇 mL) 及乙酸乙酯(500 mL)之間並分離之。以鹽水(25〇 mL)洗蘇 該有機溶液並經蒸發以產生乳酪色固體之標題化合物。 316565 37 200524846 2-溴-5-乙氧基苯曱酸甲酯 將2-溴-5-备基苯曱酸甲酯(18.9 g,81.8 mmol)、碳酸 钟(34·4 g,249.5 mmol)以及碘乙烷(13 mL,163.7 mmol)之 曱基異丁基酮(190 mL)混合物於7〇至75°c、氤氣下攪拌 15 i % hplc分析顯示完全反應成產物。添加水(1 〇〇 mL)。移除水相並以鹽水(1〇〇mL)洗滌該曱基異丁基酮溶 液,接著於真空下濃縮以產生橙色油狀之標題化合物。 2-溴-5-乙氧基苯曱酸 將2-溴-5-乙氧基苯曱酸曱酯(20·7 g,79.9 mmol)及 氫氧化鈉(4〇 mL,〇 4 mol)在四氫呋喃(1〇〇 mL)中之混 a物方;至溫下授拌1 8小時。fiPLC分析顯示起始原料已耗 盡。使該反應物冷卻至〇至並以5M鹽酸酸化至pH1。 移除有機相並以第三丁基曱基醚(4〇 mL)萃取水相。將有機 相a併,以鹽水(5〇 mL)洗滌並於真空下濃縮以產生乳酪色 固體之標題化合物。 (S)_2-{[i_(2-溴-5-乙氧基苯基)甲醯基]胺基卜3-(4,_氰基 2 ’6 -一甲氧基聯苯-4-基)丙酸甲酉旨 將二乙胺(5·5 mL,39·8 mmol)添加至(s)-2-胺基- 3-(4,-氰基2,6- 一甲氧基聯苯-4-基)丙酸甲酯鹽酸鹽(5 g 1 3 · 3 mmol)之四氫呋喃(1〇〇 mL)懸浮液。使該懸浮液於別。◦攪 拌60刀|里。以1〇分鐘時間滴加2->臭_5_乙氧基苯曱醯氣1 (3·4 g,13 mmol)之曱苯(1〇 mL)溶液(溫度維持於〇至5 °C)。將混合物於〇至5。(:下攪拌至少6〇分鐘。一旦經HpLc 分析完成,依序以2M鹽酸(25mL)、10% w/w碳酸鈉水溶 316565 38 200524846 液(25 mL)及36% w/w鹽水(25 mL)洗滌該反應混合物。蒸 德移除溶劑以得到乳酪色固體。將該乳酪色固體溶於四氫 咲喊(75 mL) ’並與以SlHcycle矽品支承之N_官能化硫脲 (〇 · 75 g)授拌一伏。過濾石夕石並使該四氫咲喃溶液濃縮至大 約30 mL。以45分鐘時間添加水(75 mL)。使該漿狀物於 室溫攪拌1小時。過濾產物、以水(30 mL)洗滌之並於40 C真空乾燥以產生灰白色固體之標題化合物。 1係使用含氯化亞硫醯(3·3當量)之甲笨(16 mL)經由標 準方法自溴乙氧基苯曱酸(3.2 g,13 mmol)製備。 (S)-2-{[l-(2-溴-5-乙氧基苯基)甲醢基]胺基}_3_(4,-氰基 -2’,6’-二曱氧基聯苯基)丙酸四氫呋喃溶劑合物 將(S)-2-{[l-(2-溴-5-乙氧基苯基)曱醯基]胺基卜3_(4,_ 氮基-2’,6’-二曱氧基聯苯基)丙酸甲酯(5 g,8·8 mrn〇1)2 四氫呋喃(25 mL)溶液冷卻至〇至5t:。滴加2M氫氧化鈉 (4·5 mL,9 mmol)(溫度維持於5。〇以下)。使該反應混合物 於0至5°C下攪拌至少18小時。一旦經HPLC分析完成, 將該混合物先以水(50 mL)稀釋再以2M鹽酸(大約1〇 mL) 調整至pHl。使所得懸浮液於〇至5艺熟化至少3〇分鐘, 再於真空下將固體遽除並以水(2〇 mL)洗務之。接著於4〇 C下真空乾燥該產物,產生灰白色固體之標題化合物。 (S)-2-{[l-(2-溴-5-乙氧基苯基)甲醯基】胺基卜3_(4,_氰基 _2’,6’-二甲氧基聯苯-4-基)丙酸(E1) 將(S)-2-{[l-(2-溴-5-乙氧基苯)甲醯基]胺基卜3-(4,_氰 39 316565 200524846 基-2,6 -一甲氧基聯笨_4-基)丙酸四氫呋喃溶劑合物(5 之甲醇(50 mL)懸浮液加熱回流並攪拌以形成溶液。使該溶 液冷卻至60°C並過濾之。接著再將該溶液以15小時時間 冷卻至0°C。使所得懸浮液於下熟化2小時。於真空下 過濾移除固體並以冰曱醇(5 mL)洗滌之。於4〇t下真空乾 無該產物’產生白色結晶狀固體之標題化合物。 實施例2 (S)-2-{[l-(2-溴-5-氟苯基)甲醯基]胺基}_3-(4,·氰基_2,,6,_ ^•甲氧基聯苯-4-基)丙酸(E1) 该標題化合物係使用P13及2-溴-5-氟苯曱醯氣(得自 Apollo)以相似於製備例u及實施例1之方法製備。 [M+H]+ at m/z 527?529 實施例3 (S)-2-{[l-(2-溴-5-甲氧基苯基)甲醯基】胺基卜3-(4,_氰基 -2’,6’-二曱氧基聯苯冰基)丙酸(E3) 實施例3a 该標述化合物可使用P7及2-漠-5-曱氧基苯曱氯(得 自Avocado)以相似於製備例11及實施例1之方法製備。 實施例3b 於室溫下將氫氧化鋰水溶液(〇·5Μ,25 mL)攪拌添加 至(S)-2-{[l-(2-溴-5-甲氧基苯基)甲醯基]胺基卜3-(4,-氰基 -2’,6’-二 T 氧基聯苯-4-基)丙酸乙酯(P12, 0.539 g5 0.95 mmol)之四氫呋喃(30 mL)溶液。持續攪拌2小時,接著再 以過量之1 0%檸檬酸水溶液終止該反應。而後使用乙酸乙 40 316565 200524846 西曰卞取。亥此合物並先後以另一份檸檬酸以及水(x 洗滌 4有機層。%發乾燥有機層並將所得粗產物藉由MDAp純 化’產生白色固體之標題化合物。[M+H]+ at m/z 539, 54卜 實施例4 ⑻-2_{[l-(2-漠甲基苯基)甲醢基】胺基卜3七,_氛基 ’6 _一甲氧基聯苯-4-基)丙酸(E4) 该標題化合物係以相似於製備例12之方法使用pi3 及2 /臭5-甲基苯甲酸(得自Apin)再將所得乙酯以實施例 3b之方法水解而製備。[M+H]+ at m/z 523, 525。 實施例5 (S) 2 {[1-(24-5-氣苯基)曱醯基】胺基卜3_(4,_氛基_2,,6,一 二甲氧基聯苯-4-基)丙酸(E5) 该標題化合物係由相對應之乙酯以相似於實施例3b 之方=製備。該乙酯係使用製備例12之方法由pl3及2_ 溴-5-虱苯曱酸(得自[⑽咖叫製備。[m_町肘m/z541, 543, 545 〇 實施例6 (S) 2-{[1-(2,5_二溴苯基)曱醯基】胺基卜3·(4,_氛基_2,,6,_二 甲氧基聯苯-4-基)丙酸(Ε6) 該標題化合物係由相對應之乙酯以相似於實施例3b 之方法製備。該乙酯係藉由製備例12之方法自卩13及2,5_ 二溴苯甲酸(得自 Lancaster)製備。[M_H]_atm/z585,587, 589。 實施例7 316565 41 200524846 (s)-2-{[i-(5-(異丙氧基)_2,苯基)甲醯基】胺基}冬[4,_氰 基-2’,6’-二甲氧基聯苯_4、基】丙酸(E7) 該標題化合㈣由相對應之乙g|以相似於實施例3b 之方法衣備。亥乙g曰係藉由製備例i 2之方法自⑴及5_ 異丙氧基-2-溴苯甲醆(係以相似於製備例8至製備例1〇之 方去衣備除了在相似於製備例9之烷化步驟使用異丙基 漠外)製備。[M-H]-atm/z 565,567。 【圖式簡單說明】 本案無圖式。 42 316565
Claims (1)
- 200524846 十、申請專利範圍: 1· 一種如式(I)之化合物或其醫藥上可接受之衍生物·(I) 式中: R1為溴;以及 R為鹵素、CN6烧基或C1-6烧氧基。 2·如申請專利範圍第1項之化合物,其中R2為鹵素或c 烷氧基。 、/ “ 3·如申請專利範圍第2項之化合物,其中R2為氟、甲 基或乙氧基。 4 4·如申請專利範圍第丨項之化合物,係選自下列所構成 群組: 之 (S)-2-{[l-(2-溴-5-曱基苯基)曱醯基]胺基卜3_(4,·氰基 _2’,6、二曱氧基聯苯_心基)丙酸; (S)-2-{[(2-溴-5-氣苯基)曱醯基]胺基卜3-[4,_氰基、2,,6,〜 二曱氧基聯苯-4-基]丙酸; · (S)-2-{[(2,5-二溴苯基)曱醯基]胺基卜3_[4,_氰基_2,,6,、 一甲氧基聯苯-4-基]丙酸; (S)-2-{[(5-(異丙氧基)-2_溴苯基)曱醯基]胺基卜3、[4,_氰 43 316565 200524846 基2 ,6 甲氧基聯苯_4_基]丙酸 或其醫藥上可接受之衍生物。 ()1[ (2 /臭、5-乙氧基苯基)曱醯基]胺基卜3-(4,-氰基 -2,6 _一甲氧基聯笨_心基)丙酸或其醫藥上可接受之 生物。 '丁 6·⑻漠I氟苯基)曱醯基]胺基卜3-(4,_氰基 -2 ’6 一甲氧基聯苯_心基)丙酸或其醫藥上可接受之 生物。 / 7· (S) U1 (2 /臭-5-甲氧基苯基)甲醯基]胺基卜3_(4,_氰基 2 ^ 一甲氧基聯笨_4-基)丙酸或其醫藥上可接受之衍 8. —種式⑴化合物之製備方法,係包括: 水解式(II)之羧酸酯衍生物:(II) (式中Rl及R2係如式⑴中所定義,以及R為可形成羧 酸酯之基團); 之後視需要可形成其醫藥上可接受之衍生物。 9·如申請專利範圍第m項中任_項之化合物,其係用 44 316565 200524846 於治療。 1 〇 · —種醫藥組成物,係包括醫療有效旦 第丨至7項中任一項之化合物與醫:上:申請專利範圍 稀釋劑之混合物。 —市丨接受之載劑或 11.一種醫藥組成物,係包括如申請專利範圍第1至工 任一項之化合物以及另一種治療活性南丨。 7員中 12·:種申請專利範圍第1至7項中任4之化合物之用 =’其係用於製造樂劑’該藥劑係用於治療或預防以媒 ”細胞黏著之α4整合素的抑制劑處理可發揮效益之病 13 · —種以媒介細胞黏著之α 效ϋ之病症之治療或預防 有效量之如申請專利範圍 投與至需要此治療之病患 4整合素之抑制劑處理可發揮 方法,該方法係包括將安全及 第1至7項中任一項之化合物 14·如申請專利範圍第13項之方法,#中該病症係選自下 列所構成之群組:類風濕性關節炎(RA);氣喘;過敏症 狀如鼻炎;成人呼吸困窘症侯群;愛滋病失智症;阿兹 海默氏症;心血管疾病;血栓或有害之血小板凝集;再 閉塞後之血栓溶解;再灌注傷害;皮膚發炎疾病如乾 癬H接靠皮膚炎及異位性皮膚炎;糖尿病(例 士騰島素依賴型糖尿病、自體免疫性糖尿病);多發 性=化症,·全身性紅斑性狼瘡(SLE);發炎性腸道疾^ 如頃瘍性結腸炎、克隆氏症(局部性腸炎)及迴腸囊袋炎 (例如.於直知大腸切除術或迴腸肛門吻合術後所產 316565 45 200524846 生);與白血球浸潤至腸胃道有關之疾病如乳糜渴、非 △'π &im與血清陰性關節病變有關之腸病變、 淋巴球性或膠原性結腸炎及嗜伊紅血球性胃腸炎;與白 血球/又/閏至其他上皮内概組織如皮膚、泌尿道、呼吸道 及關節滑膜有關之疾病;騰臟炎;乳房炎(乳腺);肝炎; 膽囊火,膽官炎或膽管周圍炎(肝臟之膽管及周圍組 ’支氣官炎’鼻竇炎、肺臟發炎疾病所導致之間質 纖維化如過敏性肺炎;膠原疾病(於SLE及RA);類肉 瘤病;骨質疏鬆症,·骨關節炎;動脈粥樣硬化;腫瘤性 疾病包括惡性腫瘤之轉移或癌性增生;創傷(促進創傷 癒合);特定眼疾如視網膜剝離、過敏性結膜炎及自體 免疫性葡萄膜炎,·修格連氏症候群;器官移植後之排斥 作用(忮性或急性);宿主對移植物或移植物對宿主疾 病;内膜增生;動脈硬化(包括移植後之移植物動脈硬 ^);手術後如經皮冠狀動脈氣球擴張術(ρτ(:Α)及經皮 冠狀動脈再開通後之再栓塞或再狹窄;腎炎;腫瘤血管 新生,惡性腫瘤;多發性骨髓瘤及骨髓瘤所誘導之骨溶 蝕作用;敗血症,·以及中枢神經系統損傷如中風、創傷 (生月回損&及脊髓損傷與梅尼爾氏症(Meniere,s disease)。 5 ·如申凊專利範圍第13項之方法,其中該病症係發炎性 腸道疾病或多發性硬化症。 16· —種如式(π)之化合物·· 46 316565 200524846(ID 式中R1及R2係如式(I)中所定義,以及R為可形成羧酸 酉旨之基團。 17. 如申請專利範圍第16項之化合物,其中R2為Cw烷氧 基或氣。 18. —種如式(III)之化合物或其酸加成鹽:(Hi) 式中R為可形成羧酸酯之基團。 19. 一種如式(VI)之化合物:(HO),丫 〇Me 47 316565 (VI) 200524846 七、指定代表圖:本案無圖式。 (一) 本案指定代表圖為:無。 (二) 本代表圖之元件代表符號簡單說明:八、本案若有化學式時,請揭示最能顯示發明特徵的化學式:⑴ 4 316565
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0329584.7A GB0329584D0 (en) | 2003-12-20 | 2003-12-20 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200524846A true TW200524846A (en) | 2005-08-01 |
Family
ID=30776207
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093138533A TW200524846A (en) | 2003-12-20 | 2004-12-13 | Novel compounds |
Country Status (19)
Country | Link |
---|---|
US (1) | US20070043113A1 (zh) |
EP (1) | EP1701933B1 (zh) |
JP (1) | JP2007513863A (zh) |
KR (1) | KR20060101534A (zh) |
CN (1) | CN1898197A (zh) |
AR (1) | AR047409A1 (zh) |
AT (1) | ATE407113T1 (zh) |
AU (1) | AU2004303687B2 (zh) |
BR (1) | BRPI0417878A (zh) |
CA (1) | CA2546943A1 (zh) |
DE (1) | DE602004016386D1 (zh) |
GB (1) | GB0329584D0 (zh) |
IL (1) | IL175921A0 (zh) |
MX (1) | MXPA06007008A (zh) |
NO (1) | NO20063342L (zh) |
RU (1) | RU2311405C1 (zh) |
TW (1) | TW200524846A (zh) |
WO (1) | WO2005061440A1 (zh) |
ZA (1) | ZA200604608B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008542407A (ja) | 2005-06-09 | 2008-11-27 | ユセベ ファルマ ソシエテ アノニム | 2,6キノリニル誘導体、それらを調製するための方法及び薬剤としてのそれらの使用 |
CN101267813A (zh) * | 2005-07-19 | 2008-09-17 | 第一三共株式会社 | 取代丙酰胺衍生物和含有其的药物组合物 |
AR059224A1 (es) | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
AR060901A1 (es) | 2006-05-12 | 2008-07-23 | Jerini Ag | Compuestos heterociclicos para la inhibicion de integrinas y uso de estos |
CN101774941A (zh) * | 2009-01-13 | 2010-07-14 | 浙江九洲药业股份有限公司 | 2-酰基氨基-3-联苯基丙酸的制备及拆分方法 |
JP7189369B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ, インコーポレイテッド | アルファ4β7インテグリンの阻害のための化合物 |
US11116760B2 (en) | 2018-10-30 | 2021-09-14 | Gilead Sciences, Inc. | Quinoline derivatives |
JP7214882B2 (ja) | 2018-10-30 | 2023-01-30 | ギリアード サイエンシーズ, インコーポレイテッド | アルファ4ベータ7インテグリン阻害剤としてのイミダゾピリジン誘導体 |
JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ, インコーポレイテッド | アルファ4ベータ7インテグリンの阻害のための化合物 |
US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY153569A (en) * | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
US6706703B2 (en) * | 2001-06-29 | 2004-03-16 | Kowa Co., Ltd. | Bis(5-aryl-2-pyridyl) derivatives |
-
2003
- 2003-12-20 GB GBGB0329584.7A patent/GB0329584D0/en not_active Ceased
-
2004
- 2004-12-13 TW TW093138533A patent/TW200524846A/zh unknown
- 2004-12-17 AT AT04807810T patent/ATE407113T1/de not_active IP Right Cessation
- 2004-12-17 MX MXPA06007008A patent/MXPA06007008A/es not_active Application Discontinuation
- 2004-12-17 US US10/581,723 patent/US20070043113A1/en not_active Abandoned
- 2004-12-17 BR BRPI0417878-5A patent/BRPI0417878A/pt not_active IP Right Cessation
- 2004-12-17 CA CA002546943A patent/CA2546943A1/en not_active Abandoned
- 2004-12-17 DE DE602004016386T patent/DE602004016386D1/de not_active Expired - Fee Related
- 2004-12-17 KR KR1020067011687A patent/KR20060101534A/ko not_active Application Discontinuation
- 2004-12-17 WO PCT/JP2004/019455 patent/WO2005061440A1/en active IP Right Grant
- 2004-12-17 RU RU2006126163/04A patent/RU2311405C1/ru not_active IP Right Cessation
- 2004-12-17 EP EP04807810A patent/EP1701933B1/en not_active Not-in-force
- 2004-12-17 CN CNA2004800382388A patent/CN1898197A/zh active Pending
- 2004-12-17 JP JP2006520437A patent/JP2007513863A/ja not_active Withdrawn
- 2004-12-17 AU AU2004303687A patent/AU2004303687B2/en not_active Ceased
- 2004-12-20 AR ARP040104788A patent/AR047409A1/es not_active Application Discontinuation
-
2006
- 2006-05-25 IL IL175921A patent/IL175921A0/en unknown
- 2006-06-06 ZA ZA200604608A patent/ZA200604608B/xx unknown
- 2006-07-19 NO NO20063342A patent/NO20063342L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2004303687A1 (en) | 2005-07-07 |
JP2007513863A (ja) | 2007-05-31 |
EP1701933B1 (en) | 2008-09-03 |
DE602004016386D1 (de) | 2008-10-16 |
BRPI0417878A (pt) | 2007-04-27 |
RU2311405C1 (ru) | 2007-11-27 |
US20070043113A1 (en) | 2007-02-22 |
EP1701933A1 (en) | 2006-09-20 |
ATE407113T1 (de) | 2008-09-15 |
AU2004303687B2 (en) | 2007-12-13 |
ZA200604608B (en) | 2007-10-31 |
CN1898197A (zh) | 2007-01-17 |
AR047409A1 (es) | 2006-01-18 |
MXPA06007008A (es) | 2006-08-31 |
KR20060101534A (ko) | 2006-09-25 |
CA2546943A1 (en) | 2005-07-07 |
IL175921A0 (en) | 2006-10-05 |
WO2005061440A1 (en) | 2005-07-07 |
GB0329584D0 (en) | 2004-01-28 |
NO20063342L (no) | 2006-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI352086B (en) | Trisubstituted amine compound | |
CN1835951B (zh) | 选择性cdk4抑制剂的羟乙基磺酸盐 | |
JP5135235B2 (ja) | Val−4によって媒介される白血球の接着を阻害するピリミジニルスルホンアミド化合物 | |
CA3047600A1 (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
CN101203519A (zh) | 用于治疗癌症和病毒感染如丙型肝炎的用作Toll样受体调节剂的2-酰氨基-6-氨基-8-氧代嘌呤衍生物 | |
EP2253625A1 (en) | Pyridazinones, the preparation and the use thereof | |
TWI281470B (en) | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins | |
WO2020001420A1 (zh) | 一类细胞坏死抑制剂及其制备方法和用途 | |
JP2003507327A (ja) | 化学化合物 | |
TW200529834A (en) | Fused heterocyclic compounds | |
TW200804369A (en) | Pyridopyrimidinone derivatives | |
TW201326138A (zh) | 犬尿胺酸-3-單氧化酶抑制劑、其醫藥組成物及其使用方法 | |
TW200827354A (en) | Composition and methods for modulating a kinase cascade | |
CN102325771B (zh) | 作为jnk调节剂的咪唑并[1,2-a]吡啶类 | |
JP2008509162A (ja) | キナゾリン誘導体と血小板血症の治療におけるその使用 | |
TW200524846A (en) | Novel compounds | |
KR20180018661A (ko) | 치환 디히드로피롤로피라졸 유도체 | |
TW201302706A (zh) | 升糖素受體調節劑 | |
TW202321263A (zh) | 磺醯胺衍生物、其製備方法及其在醫藥上的應用 | |
TW200530197A (en) | Novel compounds | |
JPH11513995A (ja) | ホスホルアミデートおよびホスフィンアミド並びにエンドテリンの活性を調節するためのその使用 | |
TW201922694A (zh) | Ido/tdo抑制劑 | |
JP7398156B2 (ja) | Stat3二機能性リン酸化部位を標的とするトリアロマティック化合物のクラスおよびその応用 | |
KR20230124555A (ko) | 갑상선 호르몬 수용체 조절제로서의 2-피리돈 | |
CN102245606A (zh) | 新化合物 |